Literature DB >> 33509238

ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism.

Valentina Tassinari1,2, Valeriana Cesarini1,3, Sara Tomaselli1, Zaira Ianniello4, Domenico Alessandro Silvestris1, Lavinia Ceci Ginistrelli4, Maurizio Martini5,6, Biagio De Angelis1, Gabriele De Luca7, Lucia Ricci Vitiani7, Alessandro Fatica4, Franco Locatelli1,8, Angela Gallo9.   

Abstract

BACKGROUND: N6-methyladenosine (m6A) and adenosine-to-inosine (A-to-I) RNA editing are two of the most abundant RNA modification events affecting adenosines in mammals. Both these RNA modifications determine mRNA fate and play a pivotal role in tumor development and progression.
RESULTS: Here, we show that METTL3, upregulated in glioblastoma, methylates ADAR1 mRNA and increases its protein level leading to a pro-tumorigenic mechanism connecting METTL3, YTHDF1, and ADAR1. We show that ADAR1 plays a cancer-promoting role independently of its deaminase activity by binding CDK2 mRNA, underlining the importance of ADARs as essential RNA-binding proteins for cell homeostasis as well as cancer progression. Additionally, we show that ADAR1 knockdown is sufficient to strongly inhibit glioblastoma growth in vivo.
CONCLUSIONS: Hence, our findings underscore METTL3/ADAR1 axis as a novel crucial pathway in cancer progression that connects m6A and A-to-I editing post-transcriptional events.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33509238      PMCID: PMC7842030          DOI: 10.1186/s13059-021-02271-9

Source DB:  PubMed          Journal:  Genome Biol        ISSN: 1474-7596            Impact factor:   13.583


  42 in total

Review 1.  Evidence-Based Practice: Temozolomide Beyond Glioblastoma.

Authors:  Jason Chua; Elizabeth Nafziger; Denise Leung
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

Review 2.  ADAR RNA editing in human disease; more to it than meets the I.

Authors:  Angela Gallo; Dragana Vukic; David Michalík; Mary A O'Connell; Liam P Keegan
Journal:  Hum Genet       Date:  2017-09-14       Impact factor: 4.132

3.  The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.

Authors:  Leng Han; Lixia Diao; Shuangxing Yu; Xiaoyan Xu; Jie Li; Rui Zhang; Yang Yang; Henrica M J Werner; A Karina Eterovic; Yuan Yuan; Jun Li; Nikitha Nair; Rosalba Minelli; Yiu Huen Tsang; Lydia W T Cheung; Kang Jin Jeong; Jason Roszik; Zhenlin Ju; Scott E Woodman; Yiling Lu; Kenneth L Scott; Jin Billy Li; Gordon B Mills; Han Liang
Journal:  Cancer Cell       Date:  2015-10-01       Impact factor: 31.743

Review 4.  Update: Mechanisms Underlying N6-Methyladenosine Modification of Eukaryotic mRNA.

Authors:  Yang Wang; Jing Crystal Zhao
Journal:  Trends Genet       Date:  2016-10-25       Impact factor: 11.639

5.  Codon-specific translation reprogramming promotes resistance to targeted therapy.

Authors:  Francesca Rapino; Sylvain Delaunay; Florian Rambow; Zhaoli Zhou; Lars Tharun; Pascal De Tullio; Olga Sin; Kateryna Shostak; Sebastian Schmitz; Jolanda Piepers; Bart Ghesquière; Latifa Karim; Benoit Charloteaux; Diane Jamart; Alexandra Florin; Charles Lambert; Andrée Rorive; Guy Jerusalem; Eleonora Leucci; Michael Dewaele; Marc Vooijs; Sebastian A Leidel; Michel Georges; Marianne Voz; Bernard Peers; Reinhard Büttner; Jean-Christophe Marine; Alain Chariot; Pierre Close
Journal:  Nature       Date:  2018-06-20       Impact factor: 49.962

Review 6.  Functions and regulation of RNA editing by ADAR deaminases.

Authors:  Kazuko Nishikura
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

Review 7.  The Editor's I on Disease Development.

Authors:  Mamta Jain; Michael F Jantsch; Konstantin Licht
Journal:  Trends Genet       Date:  2019-10-22       Impact factor: 11.639

8.  N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein.

Authors:  Nian Liu; Katherine I Zhou; Marc Parisien; Qing Dai; Luda Diatchenko; Tao Pan
Journal:  Nucleic Acids Res       Date:  2017-06-02       Impact factor: 16.971

9.  Musashi-1 promotes cancer stem cell properties of glioblastoma cells via upregulation of YTHDF1.

Authors:  Aliaksandr A Yarmishyn; Yi-Ping Yang; Kai-Hsi Lu; Yi-Chen Chen; Yueh Chien; Shih-Jie Chou; Ping-Hsing Tsai; Hsin-I Ma; Chian-Shiu Chien; Ming-Teh Chen; Mong-Lien Wang
Journal:  Cancer Cell Int       Date:  2020-12-14       Impact factor: 5.722

10.  METTL3 regulates WTAP protein homeostasis.

Authors:  Melissa Sorci; Zaira Ianniello; Sonia Cruciani; Simone Larivera; Lavinia Ceci Ginistrelli; Ernestina Capuano; Marcella Marchioni; Francesco Fazi; Alessandro Fatica
Journal:  Cell Death Dis       Date:  2018-07-23       Impact factor: 8.469

View more
  28 in total

1.  The E3 ubiquitin ligase SMURF2 stabilizes RNA editase ADAR1p110 and promotes its adenosine-to-inosine (A-to-I) editing function.

Authors:  Praveen Koganti; Venkata Narasimha Kadali; Dhanoop Manikoth Ayyathan; Andrea Emanuelli; Biagio Paolini; Gal Levy-Cohen; Michael Blank
Journal:  Cell Mol Life Sci       Date:  2022-04-11       Impact factor: 9.261

2.  ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis.

Authors:  Rajendra Karki; Balamurugan Sundaram; Bhesh Raj Sharma; SangJoon Lee; R K Subbarao Malireddi; Lam Nhat Nguyen; Shelbi Christgen; Min Zheng; Yaqiu Wang; Parimal Samir; Geoffrey Neale; Peter Vogel; Thirumala-Devi Kanneganti
Journal:  Cell Rep       Date:  2021-10-19       Impact factor: 9.423

Review 3.  Crosstalk between m6A regulators and mRNA during cancer progression.

Authors:  Xiaodong Niu; Yuan Yang; Yanming Ren; Shengtao Zhou; Qing Mao; Yuan Wang
Journal:  Oncogene       Date:  2022-08-25       Impact factor: 8.756

Review 4.  ADAR1 and its implications in cancer development and treatment.

Authors:  Allison R Baker; Frank J Slack
Journal:  Trends Genet       Date:  2022-04-19       Impact factor: 11.821

Review 5.  N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies.

Authors:  Fenghua Tan; Mengyao Zhao; Fang Xiong; Yumin Wang; Shanshan Zhang; Zhaojian Gong; Xiayu Li; Yi He; Lei Shi; Fuyan Wang; Bo Xiang; Ming Zhou; Xiaoling Li; Yong Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong; Can Guo
Journal:  J Exp Clin Cancer Res       Date:  2021-04-29

Review 6.  Cross-Talk between Oxidative Stress and m6A RNA Methylation in Cancer.

Authors:  Baishuang Yang; Qiong Chen
Journal:  Oxid Med Cell Longev       Date:  2021-08-24       Impact factor: 6.543

Review 7.  m6A modification: recent advances, anticancer targeted drug discovery and beyond.

Authors:  Li-Juan Deng; Wei-Qing Deng; Shu-Ran Fan; Min-Feng Chen; Ming Qi; Wen-Yu Lyu; Qi Qi; Amit K Tiwari; Jia-Xu Chen; Dong-Mei Zhang; Zhe-Sheng Chen
Journal:  Mol Cancer       Date:  2022-02-14       Impact factor: 27.401

8.  SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner.

Authors:  Shouji Zhang; Shulin Zhao; Yanhua Qi; Boyan Li; Huizhi Wang; Ziwen Pan; Hao Xue; Chuandi Jin; Wei Qiu; Zihang Chen; Qindong Guo; Yang Fan; Jianye Xu; Zijie Gao; Shaobo Wang; Xing Guo; Lin Deng; Shilei Ni; Fuzhong Xue; Jian Wang; Rongrong Zhao; Gang Li
Journal:  Mol Ther Nucleic Acids       Date:  2022-01-01       Impact factor: 8.886

9.  YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma.

Authors:  Rui-Chao Chai; Yu-Zhou Chang; Xin Chang; Bo Pang; Song Yuan An; Ke-Nan Zhang; Yuan-Hao Chang; Tao Jiang; Yong-Zhi Wang
Journal:  J Hematol Oncol       Date:  2021-07-10       Impact factor: 17.388

Review 10.  Interplays of different types of epitranscriptomic mRNA modifications.

Authors:  Praveenkumar Rengaraj; Aleš Obrdlík; Dragana Vukić; Nandan Mysore Varadarajan; Liam P Keegan; Štěpánka Vaňáčová; Mary A O'Connell
Journal:  RNA Biol       Date:  2021-08-23       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.